In older adults, depression not only results in more years lived with disability than any other disease but it also carries additional risks of suicide, medical comorbidities, and family caregiving burden. Because it can take many months to identify an effective treatment regimen, it is of utmost importance to shorten the window of time and identify early on what medications and dosages will work effectively for individuals having depression. Late-life depression (LLD) has been associated with greater burden of agerelated changes (eg, atrophy, white matter ischemic changes, and functional connectivity). Depression in midlife has been shown to alter affective reactivity and regulation, and functional magnetic resonance imaging (fMRI) studies in LLD have replicated the same abnormalities. Effective treatment can normalize these alterations. This article provides a review of the current literature using structural and functional neuroimaging to identify MRI predictors of treatment response in LLD. The majority of the literature on structural MRI has focused on the vascular depression hypothesis, and studies support the view that loss of brain volume and white matter integrity was associated with poorer treatment outcomes. Studies using fMRI have reported that lower taskbased activity in the prefrontal cortex and limbic regions was associated with poorer outcome. These imaging markers may be integrated into clinical decision making to attain better treatment outcomes in the future.
Introduction
Depression results in more years lived with disability than any other disease and ranks fourth in terms of disability-adjusted life-years. 1, 2 By 2020, depression will be second only to heart disease in its contribution to the global burden of disease (measured by disability-adjusted life-years). 3 As the population ages, successive cohorts of older adults will experience depressive disorders. 3 Late-life depression (LLD) carries additional risk of suicide, medical comorbidity, disability, and family caregiving burden. [4] [5] [6] Conventional treatment of LLD often requires long trials of several antidepressants before an effective regimen can be found for an individual. This can take many months and is associated with persistent depressive symptoms, an increased risk of suicide, patients dropping out of care, and worsening of medical comorbidities. This long response time is one of the most challenging clinical features of LLD. 7, 8 Thus, in the elderly individuals, it is particularly important to shorten this window and to identify early effective medication regimens. Several studies have examined the demographic, clinical, cognitive, imaging, and physiologic predictors of treatment response. [1] [2] [3] [4] [5] [6] [9] [10] [11] [12] [13] [14] [15] [16] The current review provides an update focused on the use of magnetic resonance imaging (MRI) predictors of treatment response in geriatric depression.
The current standard of care for clinical evaluation of geriatric depression uses MRI to rule out medical or neurologic causes or complications (eg, tumor or cerebral vascular accident) but does not recommend using MRI to personalize depression treatment. Although a growing literature has demonstrated that structural and functional MRI (fMRI) markers are associated with LLD treatment response, evidencebased medicine recommendations are not yet clear. 17 Part of the limitation is the paucity of randomized controlled trials testing how well imaging biomarkers can help in selecting treatment. 18 The current set of studies, however, demonstrates that MRI is a predictive biomarker of response to standard first-line antidepressant treatment. [10] [11] [12] 15, 16, Magnetic resonance imaging can be used in at least 2 different ways to inform treatment in LLD. First, the imaging markers may advise on the treatment response profile: individuals with particular imaging markers (eg, increased white matter hyperintensities [WMH] burden) may need higher initial doses of antidepressant. Second, MR markers may advise early on the trajectory of treatment response. Typically, it takes 3 to 4 weeks to see clinical signs of treatment response, significantly delaying the ability to choose the optimal medication at the optimal dose. 40 Since the standard antidepressants increase synaptic serotonin within hours of first exposure, 41 the delay in behavioral signs is attributed to a cascade of receptor remodeling stimulated by the change in synaptic serotonin. Since fMRI is able to show very early synaptic changes associated with antidepressant exposure, 42, 43 it may be used as an early predictor of treatment response. Therefore, it can help guide titration and decide when medication changes should be implemented. As far as we are aware, no studies have tested the efficacy of early functional change in a treatment. However, a number of studies have examined the functional patterns associated with treatment and treatment response. 19, 20, 23, [25] [26] [27] [28] 32, 34, 35, 39 Although these studies do not distinguish medication effects from the response, they have the potential to provide an earlier target for guiding pharmacotherapy and could be used to shorten the treatment trial interval.
Current Use of MRI in Clinical Management of LLD
As of 2012, the American Psychiatric Association (APA) primarily recommends the use of neuroimaging in an exclusionary capacity. This predominantly relates to neoplasms, cerebrovascular disease, hydrocephalus, or marked atrophy, which may be manifesting psychiatric symptoms with atypical presentations or that are otherwise not responsive to conventional treatments. 44 With respect to the APA's depression-specific guidelines, imaging is only indicated for electroconvulsive therapy's preoperative assessment of relative contraindications that mostly include the above-mentioned conditions. 45 As depression can be misdiagnosed as dementia, especially in the case of pseudo-dementia, the current recommended clinical use of neuroimaging in suspected patients with dementia is also relevant. The APA, American Neurological Association (ANA), and Alzheimer Association (AA) currently support the use of either computed tomography or MRI during the initial assessment of dementia. Again, this is meant to rule out other etiologies of cognitive impairment. With respect to the primary diagnosis of dementia, the APA and ANA do not currently recommend the routine use of diagnostic neuroimaging. 46, 47 However, in clinical research, the AA and National Institutes of Aging have together developed Alzheimer Disease (AD) neuroimaging criteria to stratify patients into stages and AD risk categories. Specifically, MRI-quantified medial temporal lobe atrophy, fludeoxyglucose-positron emission tomographic (PET), and PET amyloid imaging were deemed appropriate to assess for the presence of AD pathophysiological processes that help stratify patients within preclinical AD, mild cognitive impairment due to AD, and dementia due to AD. [48] [49] [50] [51] Finally, a joint article recently published by the AA and the Society of Nuclear Medicine and Molecular Imaging provides appropriate use criteria for PET amyloid imaging in a narrow subset of patients in clinical nonresearch settings. This patient subset includes criteria such as early-onset progressive dementia, atypical clinical course, or an etiologically mixed presentation. 52 
Structural and Functional Brain Changes Associated With Depression
It has long been recognized that the brains of older adults with depression have a greater burden of age-related changes, including atrophy, white matter ischemic changes as well as functional connectivity (FC) changes. 53, 54 Much of this work stems from the vascular depression hypothesis 55, 56 that posits that cerebrovascular changes contribute to the onset or progression of depressive symptoms in older adults primarily with lateonset LLD. Structural MRI studies have supported the vascular depression model by showing a higher burden of vascular disease in older adults with depression relative to those without depression. 56 The focus on ischemic white matter changes as a marker of cerebrovascular burden and vascular depression is specific to older adults, since in younger age groups (less than 60 years), the incidence of cerebrovascular brain changes commonly seen on MRI (ie, WMH) is rare. 57 In midlife, the MRI research has focused on identifying depression-specific functional brain changes. In a series of studies and review articles, Price and Drevets, Mayberg, and Phillips et al [58] [59] [60] have proposed functional brain circuit models for depression, which involve altered affective reactivity and regulation, that is, increased activity in rostral cingulate and limbic circuits and decreased activity in dorsal cognitive regions. These models proposed that effective treatment is associated with a normalization of these alterations. The fMRI studies in LLD have generally replicated that these same circuit abnormalities are present in older adults with depression. More recently, work from our group 61 has provided additional support to the vascular depression model by linking the structural brain changes of vascular depression with functional abnormalities. Therefore, our results showed that a higher burden of WMH is associated with greater limbic activation on an affective reactivity task.
Pretreatment Structural MRI Predictors of LLD Treatment Response
As reviewed in Table 1 , a number of studies have examined how structural MRI markers can predict response to antidepressant treatment in older adults with major depressive disorder (MDD). These studies examine whole-brain global markers as well as regional gray matter volumes, ischemic white matter burden, and white matter integrity. Across these studies, T1-weighted volumetric imaging (spoiled gradient echocardiogram or magnetization prepared rapid gradient echocardiogram 3-dimensional acquisition) was used for assessing gray matter; T2-weighted fluid-attenuated inversion recovery imaging was used to assess ischemic white matter burden by estimating the volume of WMH; white matter integrity was assessed in these studies using diffusion tensor imaging and calculating fractional anisotropy (FA) that is a marker of myelin integrity. The earliest report that we identified was by Hickie et al, 12 which studied 19 older adults with depression and found that total WMH burden and WMH restricted to the deep white matter or periventricular regions were all negatively associated with improvement in depressive symptoms. Specific criteria for recovery or remission were not reported in this study. Across the literature, criteria for defining recovery or remission vary considerably and present a challenge in integrating the literature. In Table 1 , we describe the particular criteria used in each study for defining the outcome measure. Twelve other studies with sample sizes ranging from 13 to 190 are reviewed in Table 1 . 10, 11, 15, 16, 21, 22, 24, 30, 31, [36] [37] [38] These studies have generally replicated the association of poorer treatment response with high WMH burden. The largest study involved 190 older adults with depression, those with high WMH burden having higher depression rating scores. 15 After 8 weeks of treatment, there was no significant difference in WMH burden between the remitters and the nonremitters, but there was a statistical trend (P < .09). The individuals who remitted had a lower burden of vascular risk factors. Overall, this study supports the vascular depression hypothesis, given the overall association of WMH with MADRS, and is consistent with previous reports correlating WMH burden with depression severity. The lack of significant finding with conservative remission criteria suggests that other factors (eg, cognitive performance) may be involved in attaining remission.
A smaller literature has examined with mixed results of other brain markers (gray matter volume and FA) as predictors of treatment response. Of the 3 studies, 2 found that anterior cingulate cortex and hippocampus gray matter volume were associated with poorer response, 10, 30 but the third study 31 did not a find a significant association between global or regional gray matter volume and treatment response. Three studies 21, 22, 38 that examined the treatment prediction power of FA are included in this review. The results of these studies differ: 2 of the studies found that lower FA (a marker of axonal damage) in white matter regions was associated with poorer treatment outcomes, 21, 22 but the other study found that higher FA (a marker of axonal integrity) in the white matter of the anterior cingulum and frontal cortex was associated with poorer outcomes. 38 Methodological differences between studies might explain some of the discrepancy, but the relationship between FA and treatment outcomes in LLD remains unclear.
Functional MRI Predictors of Treatment Response in Midlife Depression
Since the literature on fMRI predictors of treatment response in LLD is somewhat sparse, we first review the literature on midlife depression (Table 2) , which sets the context for reviewing the smaller number of studies in LLD. We review 8 studies in which fMRI activation is correlated with treatment response. [26] [27] [28] [29] [32] [33] [34] [35] As with the structural MRI studies described earlier, there is significant variability among these studies in the definitions of response or remission; these are in the table 2. The studies are divided into those that examine FC while the participant is awake but resting (ie, not performing a particular task) and studies that use a cognitive or affective task to probe particular circuits.
The 2 resting-state FC studies we reviewed found that resting-state fMRI markers were significantly associated with response to antidepressant treatment in a group of midlife individuals with MDD. 27, 35 The study by Lui et al 35 was a cross-sectional study comparing treatment-responsive to treatment-resistant individuals; they examined the FC among a wide range of regions identified as being involved in mood regulation and found that compared to responders, the nonresponders had significantly increased FC between the left amygdala and the cingulate cortex and between the right insula and the cingulate and precuneus. The study by Franco et al 27 used an independent component analysis method to identify the default mode network (DMN). They reported that baseline subgenual cingulate FC in the DMN was positively correlated with antidepressant treatment response, whereas dorsolateral prefrontal cortex activity was negatively correlated with antidepressant response.
Table 2 also reviews 6 task-based fMRI treatment studies of midlife depression, 5 using different affective tasks and 1 using a cognitive task. 26, 28, 29, [32] [33] [34] All of these studies reported that lower pretreatment fMRI activation in a number of prefrontal and limbic regions was associated with poorer treatment outcomes. Recent studies have focused on FC during task, and using this approach Lisiecka et al 34 show that lower orbitofrontal cortex (OFC) and motor FC during an emotional facematching task were associated with poorer treatment outcome; the reverse pattern was observed for OFC and cerebellum FC.
Functional MRI Treatment Studies in LLD
As noted earlier, there are fewer fMRI treatment studies of LLD. We found a total of 5 studies that are reviewed in Table 3 . 19, 20, 23, 25, 39 This includes 2 studies of resting-state fMRI 20,23 and 3 task-based fMRI studies (1 using a cognitive task and 2 using affective tasks). 19, 25, 39 These studies generally replicate the fMRI patterns of depression and treatment response previously reported for midlife depression: decreased task-related activity in the prefrontal cortex in LLD prior to treatment, which is normalized following treatment. 19, 25, 39 This pattern was true regardless of the task being affective or cognitive. The 2 resting-state fMRI studies found that decreased activity within the DMN was associated with poorer treatment outcomes. 20, 23 The study of Andreescu et al 23 also reported that increased FC between the posterior cingulate and the striatum was associated with poorer treatment response.
Conclusion
In summary, the preponderance of the MRI literature on treatment response in LLD has focused on structural MR following the framework of the vascular depression hypotheses. 55 These studies support the view that loss of brain volume and white matter integrity was associated with poorer treatment outcomes. The findings are most consistent for WMH burden. However, since many of the same age-related etiopathologic pathways (eg, ischemia, inflammation) leading to WMH burden will also cause gray matter atrophy and decreased white matter FA, we suspect that future studies will confirm that all structural MR markers will be associated with poorer treatment outcomes.
Most of the studies looking at fMRI as a predictor of depression treatment response have been conducted in midlife populations. These studies, which have used both resting-state and task-based fMRI, have reported that lower task-based activity in the prefrontal cortex and limbic regions was associated with poorer outcome. The resting-state fMRI results are topographically selective, showing that both increased and decreased FC were associated with poorer outcomes depending on the particular regions. Somewhat similar patterns were also reported in the LLD resting-state fMRI study by Andreescu et al. 23 In conclusion, there is a growing literature focused on both structural and fMRI treatment prediction markers in LLD. There have been some clinical reports suggesting how these markers (especially markers of cerebrovascular disease) may be integrated into clinical decision making (eg, 62 ). Future studies, including randomized clinical trials, are needed to evaluate the clinical potential of MRI markers of treatment response.
